SC
SPRY icon

Schulhoff & Co’s ARS Pharmaceuticals SPRY Stock Holding History

Schulhoff & Co’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$410K Hold
51,150
– – 0.16% 96
2026
Q1 		$411K Hold
51,150
– – 0.17% 95
2025
Q4 		$596K Buy
51,150
+7,650
+18% +$74.4K 0.25% 78
2025
Q3 		$437K Hold
43,500
– – 0.19% 90
2025
Q2 		$759K Buy
43,500
+3,000
+7% +$43.3K 0.34% 65
2025
Q1 		$509K Buy
+40,500
New +$487K 0.23% 79

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Schulhoff & Co's SPRY Position: Q2 2026 in Review

Schulhoff & Co held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 51,150 shares worth $410K. The position accounts for 0.16% of the portfolio, ranked #96.

Schulhoff & Co first reported a position in SPRY in Q1 2025 and has held it in 6 quarters since. The position peaked at $759K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Schulhoff & Co held 51,150 shares of ARS Pharmaceuticals worth $410K as of Q2 2026.
  • Schulhoff & Co left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up 0.16% of Schulhoff & Co's portfolio in Q2 2026, its #96 holding.
  • Schulhoff & Co first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Schulhoff & Co's ARS Pharmaceuticals position peaked at $759K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Schulhoff & Co's 13F filing for Q2 2026, filed 13 Aug 2026.